Trial · NCT07901569
Habitat Analysis of Tumor Thrombus for Vena Cava Wall Invasion in Renal Cell Carcinoma
NCT07901569, Not yet recruiting, Liu Zhuo
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Habitat Analysis of Tumor Thrombus for Vena Cava Wall Invasion in Renal Cell Carcinoma. Trials, record NCT07901569. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07901569
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Habitat Analysis of Tumor Thrombus for Vena Cava Wall Invasion in Renal Cell Carcinoma
- NCT number
- NCT07901569
- Status
- Not yet recruiting
- Enrollment
- 273 participants, estimated
- Lead sponsor
- Liu Zhuo
- Conditions
- Carcinoma, Renal Cell, Inferior Vena Cava Tumor Thrombus
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Diagnostic Performance (AUROC) of Preoperative CT/MRI Habitat Imaging for Inferior Vena Cava Wall Invasion | within 8 weeks after the surgery | The study team will measure the diagnostic performance of a habitat imaging model. The model uses preoperative contrast-enhanced CT and MRI. The target condition is inferior vena cava wall invasion. The reference standard is the structured pathology report from surgery. The primary metric is the area under the receiver operating characteristic curve (AUROC) with the 95% confidence interval. The team will also report sensitivity and specificity at a pre-specified threshold. The team will use nested cross-validation and bootstrap for internal validation. Calibration and clinical utility are secondary endpoints. |
| Secondary | Calibration of the Habitat Model | within 8 weeks after the surgery | The study team assesses calibration with intercept, slope, and Brier score. The team reports calibration plots. |
| Secondary | Clinical Utility of the Habitat Model (Decision Curve Analysis) | within 8 weeks after the surgery | The study team assesses clinical utility with decision curve analysis. The team reports net benefit across threshold probabilities. |
| Secondary | Incremental Value over Conventional Signs, Whole-tumor Radiomics, and Clinical Models | within 8 weeks after the surgery | The study team compares the habitat model with a conventional sign model, a whole-tumor radiomics model, and a clinical model. The team reports AUROC differences with 95% confidence intervals. |
| Secondary | Imaging-Pathology Agreement for Wall Invasion | within 8 weeks after the surgery | Two pathologists read each pathology report independently. The study team calculates agreement for wall invasion. The team reports Cohen kappa and the number of disagreements. A third pathologist resolves disagreements. |
| Secondary | Pathology Grading Agreement for Wall Invasion | within 8 weeks after the surgery | The study team calculates agreement for the pathology grading of wall invasion. The team reports Cohen kappa and the number of disagreements. A third pathologist resolves disagreements. |
| Secondary | Batch Effects by Scanner, Slice Thickness, and Reconstruction Kernel | within 8 weeks after the surgery | The study team compares feature variance components and AUROC across acquisition batches. The team tests the assumptions of ComBat before use. If the team uses ComBat, the team also reports unadjusted results. |
| Secondary | Spatial Transcriptomic Validation of Imaging Habitats | within 8 weeks after the surgery | The study team compares imaging habitats with spatial transcriptomic regions. The team uses available Visium data from seven tissue sections. The data come from two participants. The team maps each habitat to the transcriptomic regions in the same tissue block when possible. The team reports the correspondence descriptively. The analysis is exploratory. |
| Secondary | Habitat-associated Transcriptomic Signatures | within 8 weeks after the surgery | The study team tests habitat-associated gene expression signatures. The signatures include hypoxia, immune response, epithelial-mesenchymal transition, and tertiary lymphoid structure genes. The team compares signature scores across habitats. The analysis is exploratory. |
| Secondary | Paired Invasion versus Non-invasion Region Comparison | within 8 weeks after the surgery | One participant has paired invasion and non-invasion tissue sections. The study team compares habitat composition between the two regions. The team compares transcriptomic signatures between the two regions. The analysis is exploratory. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07901569
GET https://conductscience.org/api/trials/v1/NCT07901569/registered